A Phase 3 interventional study of Herpes Zoster vaccine GSK1437173A and Placebo in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 34 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-01.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.
Among the 46 studies testing shingrix in Herpes Zoster, this one is the 22nd largest by enrollment, is one of 5 that started in 2014, is one of 22 in phase 3, and was the 14th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
Loyola University · Sites in United States
University of Colorado, Denver · Sites in United States
Ages 18–70
By country, each count listing its studies:
shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 22 · Phase 4 8
First in 2009; this study’s year is marked. 5 started in 2014.
This study's enrollment of 265 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 239 across the 46 interventional studies. Of the 32 that completed or were terminated, 27 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Herpes Zoster by GlaxoSmithKline: 3 open now, 5 under way, 1 of them phase 3. Of 39 finished, 34 (87%) have results posted.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 26th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2014, is one of 25 in phase 3, and was the 24th registered.
GlaxoSmithKline’s Herpes Zoster studies by the year they started, since 2007.
4 of the studies testing shingrix in Herpes Zoster that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
| NCT05580458National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population | 2027-02-01 |
| NCT06162494Ann & Robert H Lurie Children's Hospital of ChicagoRecombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients | 2027-03-31 |
| NCT06569823Dynavax Technologies CorporationSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies testing shingrix in Herpes Zoster, from their registry updates:
Among GlaxoSmithKline’s 44 in Herpes Zoster:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine administered on a 0- and 1- to 2-months schedule in adults 18 years of age or older who are receiving chronic immunosuppressive therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject with stable renal function, stability defined as:
Female subjects of childbearing potential may be enrolled in the study, if the subject:
Exclusion Criteria:
Previous allograft loss secondary to recurrent primary kidney disease.
Acute disease and/or fever at the time of vaccination.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects, aged 18 years or older, received 2 doses of the GSK 1437173A vaccine, adjuvanted with AS01B at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.
Biological: Herpes Zoster vaccine GSK1437173A
Subjects, aged 18 years or older, received 2 doses of Placebo (lyophilised sucrose reconstituted with saline \[NaCl\] solution) at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.
Drug: Placebo
2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Number of Subjects With a Vaccine Response for Anti-glycoprotein E (gE) Humoral Immunogenicity
Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination greater than or equal to (≥) 4 fold the cut-off for Anti-gE (4x97 milli-international units per milliliter \[mIU/ml\]); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration. Vaccine response was determined by Enzyme-Linked ImmunoSorbent Assay (ELISA).
Time frame: At Month 2.
Number of Subjects With Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Pain when limb was moved, which prevented everyday activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: Within 7 days (Days 0-6) after each dose and across doses.
Days With Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling.
Time frame: Within 7 days (Days 0-6) after each dose and overall/dose
Number of Subjects With Solicited General Symptoms
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\] . Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. Gastrointestinal symptoms (Gastro. sympt.) included nausea, vomiting, diarrhoea and/or abdominal pain.
Time frame: Within 7 days (Days 0-6) after each dose and across doses
Days With Solicited General Symptoms
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\].
Time frame: Within 7 days (Days 0-6) after each dose and overall/dose
Number of Subjects With Unsolicited Symptoms (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: During the 30-day (Days 0-29) post-vaccination period
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology
Time frame: From first vaccination (Month 0) up to 1 month post last vaccination (Month 2).
Number of Subjects With Any and Related Serious Adverse Events (SAEs)
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongatoion of hospitalization, or result in disability /incapacity. Related = SAE assessed by the investigator as related to the vaccination.
Time frame: From first vaccination (Month 0) up to 1 month post last vaccination (Month 2).
Number of Subjects With Renal Allograft Rejection
Renal allograft rejection was confirmed through biopsy.
Time frame: From the first vaccination (Month 0) up to 1 month post last vaccination (Month 2).
Number of Subjects With Changes in Allograft Function
Allograft function was indicated by the increase in levels of serum creatinine (≥ 1.20, ≥ 1.50, ≥ 1.75 or ≥ 2 fold increase). The number of subjects with declining allograft function, as determined by serum creatinine measurements post-vaccination (up to 30 days post-last vaccination) compared to pre-vaccination were presented.
Time frame: From the first vaccination (Month 0) up to 1 month post last vaccination (Month 2).
Anti-gE Antibody Concentrations
Varicella Zoster Virus (VZV) gE antibody Immunoglobulin G concentrations were determined by ELISA assay, presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The reference seropositivity cut-off value was ≥ 97 mIU/mL.
Time frame: At Months 0, 1, 2, 7 and 13
Number of Subjects With a Vaccine Response for Anti-gE Humoral Immunogenicity
Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination greater than or equal to (≥) 4 fold the cut-off for Anti-gE (4x97 mIU/mL); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration. Vaccine response was determined by ELISA.
Time frame: At Months 1, 7 and 13
Frequencies of gE-specific Cluster of Differentiation 4 (CD4+) T-cells
Descriptive statistics of gE-specific CD4+ T-cells, expressing at least two activation markers (from among interferon gamma \[IFN-γ\], interleukin-2 \[IL-2\], tumour necrosis factor alpha \[TNF-α\] and cluster of differentiation 40-ligand \[CD40L\]) were tabulated, as determined by in vitro Intracellular Cytokine Staining (ICS).
Time frame: At Months 0, 2 and 13
Number of Subjects With a Vaccine Response for gE-specific CD4+ T-cells
Vaccine response for gE-specific CD4+ T-cells expressing at least two activation markers (from among IFN-γ, IL-2, TNF-α and CD40L), was determined by in vitro ICS. Vaccine response was defined as: For initially subjects with pre-vaccination T-cell frequencies below the threshold, at least a 2-fold increase as compared to the threshold (2x\<320\> Events/10 million CD4+ T-cells); For initially subjects with pre-vaccination T-cell frequencies above the threshold, at least a 2-fold increase as compared to pre-vaccination T-cell frequencies.
Time frame: At Months 2 and 13
Number of Subjects With Any and Related SAEs
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related = SAE assessed by the investigator as related to the vaccination.
Time frame: From 1 month post last vaccination (Month 2) until study end (Month 13).
Number of Subjects With Any pIMDs
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Time frame: From 1 month post last vaccination (Month 2) until study end (Month 13).
Number of Subjects With Renal Allograft Rejection
Renal allograft rejection was confirmed through biopsy.
Time frame: From 1 month post last vaccination (Month 2) until study end (Month 13).
Number of Subjects With Changes in Allograft Function
Allograft function was indicated by the increase in levels of serum creatinine (≥ 1.20, ≥ 1.50, ≥ 1.75 or ≥ 2 fold increase). The number of subjects with declining allograft function, as determined by serum creatinine measurements post-vaccination (from 30 days post-last vaccination up to study end) compared to pre-vaccination were presented.
Time frame: From 1 month post last vaccination (Month 2) until study end (Month 13)
| Milestone | GSK1437173A Group | Control Group |
|---|---|---|
| Started | 132 | 132 |
| Completed | 130 | 130 |
| Not completed | 2 | 2 |
| Withdrew: Serious adverse event | 1 | 1 |
| Withdrew: Non-serious adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination greater than or equal to (≥) 4 fold the cut-off for Anti-gE (4x97 milli-international units per milliliter \[mIU/ml\]); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration. Vaccine response was determined by Enzyme-Linked ImmunoSorbent Assay (ELISA).
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Number of Subjects With a Vaccine Response for Anti-glycoprotein E (gE) Humoral Immunogenicity | 97 | 5 |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Pain when limb was moved, which prevented everyday activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Any Pain, Dose 1 | 107 | 8 |
| Grade 3 Pain, Dose 1 | 10 | 0 |
| Any Redness, Dose 1 | 24 | 1 |
| Grade 3 Redness, Dose 1 | 0 | 0 |
| Any Swelling, Dose 1 | 10 | 1 |
| Grade 3 Swelling, Dose 1 | 0 | 0 |
| Any Pain, Dose 2 | 93 | 6 |
| Grade 3 Pain, Dose 2 | 9 | 0 |
| Any Redness, Dose 2 | 21 | 1 |
| Grade 3 Redness, Dose 2 | 1 | 0 |
| Any Swelling, Dose 2 | 11 | 0 |
| Grade 3 Swelling, Dose 2 | 1 | 0 |
| Any Pain, Across doses | 114 | 11 |
| Grade 3 Pain, Across doses | 13 | 0 |
| Any Redness, Across doses | 33 | 2 |
| Grade 3 Redness, Across doses | 1 | 0 |
| Any Swelling, Across doses | 15 | 1 |
| Grade 3 Swelling, Across doses | 1 | 0 |
Assessed solicited local symptoms were pain, redness and swelling.
| Days | GSK1437173A Group | Control Group |
|---|---|---|
| Pain, Dose 1 | 3.0 (2.0 to 4.0) | 1.5 (1.0 to 2.5) |
| Pain, Dose 2 | 3.0 (2.0 to 3.0) | 1.0 (1.0 to 2.0) |
| Pain, Overall | 3.0 (2.0 to 4.0) | 1.0 (1.0 to 2.0) |
| Redness, Dose 1 | 4.0 (2.5 to 6.5) | 4.0 (4.0 to 4.0) |
| Redness, Dose 2 | 3.0 (2.0 to 7.0) | 2.0 (2.0 to 2.0) |
| Redness, Overall | 4.0 (2.0 to 7.0) | 3.0 (2.0 to 4.0) |
| Swelling, Dose 1 | 4.0 (2.0 to 7.0) | 4.0 (4.0 to 4.0) |
| Swelling, Dose 2 | 4.0 (1.0 to 5.0) | — |
| Swelling, Overall | 4.0 (2.0 to 6.0) | 4.0 (4.0 to 4.0) |
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\] . Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. Gastrointestinal symptoms (Gastro. sympt.) included nausea, vomiting, diarrhoea and/or abdominal pain.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Any Fatigue, Dose 1 | 47 | 42 |
| Grade 3 Fatigue, Dose 1 | 3 | 3 |
| Related Fatigue, Dose 1 | 8 | 2 |
| Any Gastro. sympt., Dose 1 | 17 | 16 |
| Grade 3 Gastro. sympt., Dose 1 | 1 | 0 |
| Related Gastro. sympt., Dose 1 | 1 | 1 |
| Any Headache, Dose 1 | 32 | 25 |
| Grade 3 Headache, Dose 1 | 1 | 4 |
| Related Headache, Dose 1 | 5 | 3 |
| Any Myalgia, Dose 1 | 43 | 23 |
| Grade 3 Myalgia, Dose 1 | 4 | 1 |
| Related Myalgia, Dose 1 | 11 | 2 |
| Any Shivering, Dose 1 | 10 | 13 |
| Grade 3 Shivering, Dose 1 | 0 | 1 |
| Related Shivering, Dose 1 | 3 | 2 |
| Any Temperature, Dose 1 | 13 | 6 |
| Grade 3 Temperature, Dose 1 | 0 | 0 |
| Related Temperature, Dose 1 | 3 | 0 |
| Any Fatigue, Dose 2 | 49 | 36 |
| Grade 3 Fatigue, Dose 2 | 4 | 4 |
| Related Fatigue, Dose 2 | 8 | 4 |
| Any Gastro. sympt., Dose 2 | 14 | 14 |
| Grade 3 Gastro. sympt., Dose 2 | 0 | 1 |
| Related Gastro. sympt., Dose 2 | 1 | 2 |
| Any Headache, Dose 2 | 35 | 22 |
| Grade 3 Headache, Dose 2 | 2 | 3 |
| Related Headache, Dose 2 | 9 | 1 |
| Any Myalgia, Dose 2 | 47 | 19 |
| Grade 3 Myalgia, Dose 2 | 8 | 3 |
| Related Myalgia, Dose 2 | 14 | 3 |
| Any Shivering, Dose 2 | 23 | 9 |
| Grade 3 Shivering, Dose 2 | 4 | 2 |
| Related Shivering, Dose 2 | 9 | 0 |
| Any Temperature, Dose 2 | 21 | 7 |
| Grade 3 Temperature, Dose 2 | 1 | 0 |
| Related Temperature, Dose 2 | 6 | 0 |
| Any Fatigue, Across doses | 62 | 53 |
| Grade 3 Fatigue, Across doses | 4 | 6 |
| Related Fatigue, Across doses | 15 | 4 |
| Any Gastro. sympt., Across doses | 24 | 24 |
| Grade 3 Gastro. sympt., Across doses | 1 | 1 |
| Related Gastro. sympt.,Across doses | 2 | 3 |
| Any Headache, Across doses | 44 | 34 |
| Grade 3 Headache, Across doses | 2 | 5 |
| Related Headache, Across doses | 12 | 4 |
| Any Myalgia, Dose Across doses | 65 | 31 |
| Grade 3 Myalgia, Dose Across doses | 9 | 3 |
| Related Myalgia, Dose Across doses | 21 | 4 |
| Any Shivering, Dose Across doses | 29 | 16 |
| Grade 3 Shivering, Dose Across doses | 4 | 2 |
| Related Shivering, Dose Across doses | 11 | 2 |
| Any Temperature, Dose Across doses | 31 | 13 |
| Grade 3 Temperature, Dose Across doses | 1 | 0 |
| Related Temperature, Dose Across doses | 9 | 0 |
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\].
| Days | GSK1437173A Group | Control Group |
|---|---|---|
| Fatigue, Dose 1 | 3.0 (2.0 to 6.0) | 3.0 (1.0 to 7.0) |
| Fatigue, Dose 2 | 3.0 (2.0 to 5.0) | 4.5 (2.0 to 7.0) |
| Fatigue, Overall | 3.0 (2.0 to 5.5) | 4.0 (2.0 to 7.0) |
| Gastrointestinal symptoms, Dose 1 | 2.0 (1.0 to 2.0) | 3.5 (1.0 to 4.5) |
| Gastrointestinal symptoms, Dose 2 | 2.0 (1.0 to 2.0) | 2.0 (1.0 to 3.0) |
| Gastrointestinal symptoms, Overall | 2.0 (1.0 to 2.0) | 2.0 (1.0 to 4.0) |
| Headache, Dose 1 | 1.0 (1.0 to 2.0) | 2.0 (1.0 to 3.0) |
| Headache, Dose 2 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 4.0) |
| Headache, Overall | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) |
| Myalgia, Dose 1 | 3.0 (2.0 to 4.0) | 3.0 (1.0 to 7.0) |
| Myalgia, Dose 2 | 2.0 (1.0 to 4.0) | 7.0 (2.0 to 7.0) |
| Myalgia, Overall | 3.0 (1.0 to 4.0) | 5.0 (1.0 to 7.0) |
| Shivering, Dose 1 | 2.0 (1.0 to 4.0) | 2.0 (1.0 to 7.0) |
| Shivering, Dose 2 | 1.0 (1.0 to 2.0) | 3.0 (2.0 to 7.0) |
| Shivering, Overall | 1.0 (1.0 to 2.0) | 2.5 (1.0 to 7.0) |
| Temperature, Dose 1 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| Temperature, Dose 2 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| Temperature, Overall | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| At least one symptom | 51 | 44 |
| Subjects with grade 3 AEs | 7 | 5 |
| Subjects with related AEs | 7 | 3 |
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) | 0 | 0 |
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongatoion of hospitalization, or result in disability /incapacity. Related = SAE assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Any SAEs | 6 | 5 |
| Related SAEs | 0 | 0 |
Renal allograft rejection was confirmed through biopsy.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Rejection confirmed | 0 | 0 |
| Rejection not confirmed | 0 | 3 |
Allograft function was indicated by the increase in levels of serum creatinine (≥ 1.20, ≥ 1.50, ≥ 1.75 or ≥ 2 fold increase). The number of subjects with declining allograft function, as determined by serum creatinine measurements post-vaccination (up to 30 days post-last vaccination) compared to pre-vaccination were presented.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| ≥1.20 fold increase | 5 | 7 |
| ≥1.50 fold increase | 0 | 1 |
| ≥1.75 fold increase | 0 | 1 |
| ≥2 fold increase | 0 | 1 |
Varicella Zoster Virus (VZV) gE antibody Immunoglobulin G concentrations were determined by ELISA assay, presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The reference seropositivity cut-off value was ≥ 97 mIU/mL.
| mIU/mL | GSK1437173A Group | Control Group |
|---|---|---|
| anti-gE, Month 0 | 1354.4 (1118.3 to 1640.4) | 1495.7 (1202.3 to 1860.8) |
| anti-gE, Month 1 | 9530.5 (7111.3 to 12772.7) | 1501.9 (1231.3 to 1832.0) |
| anti-gE, Month 2 | 19163.8 (15041.5 to 24416.0) | 1489.4 (1215.8 to 1824.7) |
| anti-gE, Month 7 | 13066.7 (10291.5 to 16590.4) | 1533.7 (1249.6 to 1882.3) |
| anti-gE, Month 13 | 8545.1 (6753.7 to 10811.5) | 1572.7 (1269.6 to 1948.1) |
Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination greater than or equal to (≥) 4 fold the cut-off for Anti-gE (4x97 mIU/mL); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration. Vaccine response was determined by ELISA.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| anti-gE, Month 1 | 77 | 3 |
| anti-gE, Month 7 | 83 | 5 |
| anti-gE, Month 13 | 74 | 7 |
Descriptive statistics of gE-specific CD4+ T-cells, expressing at least two activation markers (from among interferon gamma \[IFN-γ\], interleukin-2 \[IL-2\], tumour necrosis factor alpha \[TNF-α\] and cluster of differentiation 40-ligand \[CD40L\]) were tabulated, as determined by in vitro Intracellular Cytokine Staining (ICS).
| gE-specific CD4+ T-cells/million T-cells | GSK1437173A Group | Control Group |
|---|---|---|
| Month 0 | 110.9 ± 182.09 | 165.75 ± 242.92 |
| Month 2 | 2433.07 ± 2102.29 | 156.98 ± 274.81 |
| Month 13 | 1320.92 ± 1823.64 | 129.41 ± 197.92 |
Vaccine response for gE-specific CD4+ T-cells expressing at least two activation markers (from among IFN-γ, IL-2, TNF-α and CD40L), was determined by in vitro ICS. Vaccine response was defined as: For initially subjects with pre-vaccination T-cell frequencies below the threshold, at least a 2-fold increase as compared to the threshold (2x\<320\> Events/10 million CD4+ T-cells); For initially subjects with pre-vaccination T-cell frequencies above the threshold, at least a 2-fold increase as compared to pre-vaccination T-cell frequencies.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Month 2 | 20 | 0 |
| Month 13 | 17 | 0 |
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related = SAE assessed by the investigator as related to the vaccination.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Any SAEs | 21 | 29 |
| Related SAEs | 0 | 1 |
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Number of Subjects With Any pIMDs | 4 | 2 |
Renal allograft rejection was confirmed through biopsy.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| Rejection confirmed | 4 | 7 |
| Rejection not confirmed | 12 | 13 |
Allograft function was indicated by the increase in levels of serum creatinine (≥ 1.20, ≥ 1.50, ≥ 1.75 or ≥ 2 fold increase). The number of subjects with declining allograft function, as determined by serum creatinine measurements post-vaccination (from 30 days post-last vaccination up to study end) compared to pre-vaccination were presented.
| Participants | GSK1437173A Group | Control Group |
|---|---|---|
| ≥1.20 fold increase | 17 | 22 |
| ≥1.50 fold increase | 4 | 3 |
| ≥1.75 fold increase | 3 | 1 |
| ≥2 fold increase | 2 | 0 |
Collected over Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period, Unsolicited symptoms: during the 30-day (Days 0-29) post-vaccination period, Serious Adverse Events: from Month 0 up to study end at Month 13.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK1437173A Group | 1/132 (0.8%) | 26/132 (19.7%) | 121/132 (91.7%) |
| Placebo Group | 1/132 (0.8%) | 33/132 (25%) | 78/132 (59.1%) |
| Event | GSK1437173A Group | Placebo Group |
|---|---|---|
| Transplant rejectionImmune system disorders | 2/132 | 4/132 |
| GastroenteritisInfections and infestations | 2/132 | 4/132 |
| Herpes zosterInfections and infestations | 0/132 | 4/132 |
| Pyelonephritis acuteInfections and infestations | 4/132 | 1/132 |
| InfluenzaInfections and infestations | 3/132 | 0/132 |
| Urinary tract infectionInfections and infestations | 2/132 | 3/132 |
| Blood creatinine increasedInvestigations | 0/132 | 3/132 |
| Kidney transplant rejectionImmune system disorders | 1/132 | 2/132 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/132 | 1/132 |
| Atrial fibrillationCardiac disorders | 0/132 | 1/132 |
| Event | GSK1437173A Group | Placebo Group |
|---|---|---|
| PainGeneral disorders | 114/132 | 11/132 |
| MyalgiaMusculoskeletal and connective tissue disorders | 65/132 | 31/132 |
| FatigueGeneral disorders | 62/132 | 54/132 |
| HeadacheNervous system disorders | 44/132 | 35/132 |
| ErythemaSkin and subcutaneous tissue disorders | 33/132 | 2/132 |
| PyrexiaGeneral disorders | 32/132 | 14/132 |
| ChillsGeneral disorders | 29/132 | 16/132 |
| Gastrointestinal disorderGastrointestinal disorders | 24/132 | 24/132 |
| SwellingGeneral disorders | 15/132 | 1/132 |
| Age, Continuous(Years) | GSK1437173A Group | Control Group | Total |
|---|---|---|---|
| Geometric mean | 52.3 ± 12.5 | 52.4 ± 12.8 | 52.4 ± 12.6 |
| Sex: Female, Male(Participants) | GSK1437173A Group | Control Group | Total |
|---|---|---|---|
| Female | 38 | 41 | 79 |
| Male | 94 | 91 | 185 |
| Race/Ethnicity, Customized(Participants) | GSK1437173A Group | Control Group | Total |
|---|---|---|---|
| African Heritage / African American | 3 | 1 | 4 |
| Asian - Central/South Asian Heritage | 1 | 2 | 3 |
| Asian - East Asian Heritage | 20 | 22 | 42 |
| Asian - Japanese Heritage | 0 | 1 | 1 |
| Asian - South East Asian Heritage | 10 | 3 | 13 |
| White - Arabic / North African Heritage | 2 | 2 | 4 |
| White - Caucasian / European Heritage | 88 | 97 | 185 |
| Unspecified | 8 | 4 | 12 |
Ran from Mar 2014 to primary completion in May 2016, 25 months.
Results were first posted in Aug 2018, 2 years 2 months after primary completion.
Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 25 months is above that.
Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Shingrix